AsclepiX Therapeutics Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 8
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $35M
Latest Deal Amount
  • Investors
  • 14

AsclepiX Therapeutics General Information

Description

Developer of biomimetic anti-angiogenic and anti-lymphangiogenic peptides designed to transform the treatment of retinal disease and cancer through the rapid clinical development of groundbreaking therapies. The company's peptides are used for indications in ophthalmology, oncology and for other angiogenesis and lymphangiogenesis-dependent diseases, enabling patients and doctors to better treat ocular ailments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Other Pharmaceuticals and Biotechnology
Primary Office
  • 301 West 29th Street
  • Suite 2004
  • Baltimore, MD 21211
  • United States
+1 (610) 000-0000

AsclepiX Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AsclepiX Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series A) 24-Jun-2020 $35M 0000 0000 Completed Generating Revenue
6. Grant 01-Jan-2019 00000 Completed Generating Revenue
5. Grant 01-Jan-2017 00.00 Completed Generating Revenue
4. Grant 01-Sep-2015 00000 Completed Generating Revenue
3. Grant 24-Jul-2014 00.000 Completed Generating Revenue
2. Accelerator/Incubator 25-Jun-2014 Completed Generating Revenue
1. Grant 15-Jun-2013 $100K Completed Generating Revenue
To view AsclepiX Therapeutics’s complete valuation and funding history, request access »

AsclepiX Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of biomimetic anti-angiogenic and anti-lymphangiogenic peptides designed to transform the treatment of retinal
Drug Discovery
Baltimore, MD
8 As of 2021
0000
000 0000-00-00
00000000000 0000

0000000

cididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamc
0000 000000000
Jena, Germany
00 As of 0000
00000
000000 - 000 00000

00000000

r adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad min
0000 000000000
Seattle, WA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AsclepiX Therapeutics Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
InflaRx Formerly VC-backed Jena, Germany 00 00000 000000 - 000 00000
000000000000 Venture Capital-Backed Seattle, WA 00 00000 00000000000 00000
0000000 Formerly VC-backed Waltham, MA 000 00000 000000 - 000 00000
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000 00000
000000 00000000000 Venture Capital-Backed Weston, FL 0 000.00 00000000000 000.00
You’re viewing 5 of 30 competitors. Get the full list »

AsclepiX Therapeutics Patents

AsclepiX Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3661536-A4 Methods for identifying and preparing pharmaceutical agents for activating tie2 receptor Pending 03-Aug-2017 0000000000 0
EP-3661536-A1 Methods for identifying and preparing pharmaceutical agents for activating tie2 receptor Pending 03-Aug-2017 0000000000
US-20210132062-A1 Methods for identifying and preparing pharmaceutical agents for activating tie2 receptor Pending 03-Aug-2017 000000000000
EP-3522906-A1 Compounds and methods for activating tie2 signaling Pending 04-Oct-2016 000000000
CA-3038809-A1 Compounds and methods for activating tie2 signaling Pending 04-Oct-2016 A61K38/39
To view AsclepiX Therapeutics’s complete patent history, request access »

AsclepiX Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
Robert Dempsey Board Member, Chief Executive Officer & President
Jordan Green Ph.D Co-Founder, Board Member, Chief Technology Advisor & Chief Technology Officer
Aleksander Popel Ph.D Co-Founder & Chief Scientific Advisor
Amir Shojaei Ph.D Chief Scientific Officer & Executive Vice President
You’re viewing 4 of 6 executive team members. Get the full list »

AsclepiX Therapeutics Board Members (8)

Name Representing Role Since
Ben Askew Ph.D Self Board Member 000 0000
Christopher Garabedian Perceptive Advisors Board Member 000 0000
Joshua Barer Barer & Son Capital Board Member 000 0000
Robert Dempsey AsclepiX Therapeutics Board Member, Chief Executive Officer & President 000 0000
Sapna Srivastava Ph.D Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

AsclepiX Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AsclepiX Therapeutics Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Barer & Son Capital Venture Capital Minority 000 0000 000000 0
Hibiscus Capital Management Venture Capital Minority 000 0000 000000 0
Perceptive Advisors Hedge Fund Minority 000 0000 000000 0
Piedmont Capital Partners Merchant Banking Firm 000 0000 000000 0
Rapha Capital Management Corporation 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »